Repligen Co. (NASDAQ:RGEN) Shares Sold by Cynosure Group LLC

Cynosure Group LLC trimmed its holdings in Repligen Co. (NASDAQ:RGEN) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,877 shares of the biotechnology company’s stock after selling 147 shares during the quarter. Cynosure Group LLC’s holdings in Repligen were worth $428,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Champlain Investment Partners LLC grew its position in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after buying an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its stake in Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after acquiring an additional 36,773 shares during the period. Finally, New York State Common Retirement Fund increased its holdings in shares of Repligen by 14.4% in the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after purchasing an additional 71,274 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ RGEN opened at $149.99 on Thursday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.40 billion, a price-to-earnings ratio of -405.37, a price-to-earnings-growth ratio of 4.40 and a beta of 0.96. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The business has a fifty day moving average of $140.74 and a 200-day moving average of $142.89.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the company earned $0.23 EPS. As a group, analysts predict that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on RGEN shares. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Wells Fargo & Company began coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. UBS Group cut their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.